19th Annual Drug Discovery Summit and 6th Annual Discovery Chemistry and Drug Design Congress

Join Oxford Global’s 19^th Annual Drug Discovery Summit on the 7- 8^th June 2018 in Berlin, Germany to explore the latest innovations pushing industry to new heights. This congress will cover such areas as innovation, enabling technologies, new modalities and novel drug targets as well as covering key areas such as phenotypic screening, genome based drug discovery and small molecule drug discovery.

Bringing together over 300 senior level peers, the congress is once again co-located with our 6^th Annual Discovery Chemistry and Drug Design Congress. Delegates can expect to hear updates on discovery, medicinal and computational chemistry as well as medicinal chemistry in drug design. New for 2018 we’ll be including deep dive sessions on DNA encoded libraries as well as presentations on data visualisation, protein-protein interactions and protein degradation.

VIEW AGENDA: http://bit.ly/2mqWK5m

Drug Discovery Summit Streams:

• Drug Discovery Innovation and Strategies
• Successful Phenotypic Drug Discovery and Other High Content Screening Tools
• Novel Drug Target Discovery for Immuno-Therapy, Autoimmune Diseases and Oncology
• Genome Based Drug Discovery, Screening, Imaging & Target Discovery

Discovery Chemistry & Drug Design Congress Streams:

• Discovery Chemistry, Medicinal and Computational Chemistry
• Drug Discovery Enabled Technologies; DNA Encoded Libraries
• Medicinal Chemistry and Drug Design: Novel Approaches

Drug Discovery Free Webinar Recordings:

Webinar 1: Nanobodies as a Versatile and Clinically Validated Approach
Speaker: Tony De Fougerolles, Chief Scientific Officer at Ablynx

Webinar 2: Open Innovation and partnerships for an improved Lead Generation
Speaker: Patrick Jimonet, External Opportunities in Drug Discovery, Sanofi

Webinar 3: Drug Discovery Open Innovation and Outsourcing
Speaker 1: Patrick Kleyn, Director of Drug Target Innovation, EMD Serono
Speaker 2: Garry Pairaudeau, Senior Director, Head of External Sciences, AstraZeneca

Webinar 4: Phenotypic Screening in Drug Discovery- Novel Tools & Applications
Speaker 1: Paul Andrews, Director of Operations, National Phenotypic Screening Centre (NPSC), School of Life Sciences, University of Dundee
Speaker 2: Joost Uitdehaag, Senior Investigator at Netherlands Translational Research Center B.V.

Webinar 5: Disruptive Technologies & Artificial Intelligence in Drug Discovery
Speaker: Chris Gibson, CEO, Recursion Pharmaceuticals

Download For Free Today: http://bit.ly/2hvb2g5

Alexander Alanine, Chief Operating Officer
Bactevo

Vivek K Vishnudas, Chief Technology Officer
Berg Health

Thomas Franch, Chief Scientific Officer
Nuevolution

Thorsten Thormann, Senior Vice President New Product Discovery
LEO Pharma

Anna Maroney, Vice President, Head of Alliance Management
AbbVie

Yolanda Chong, Vice President Biology
Recursion Pharmaceuticals

Juergen Gamer, Vice President Business Development
Apogenix

Philip Tagari, Vice President Research
Amgen

Petre Vachal, Vice President Discovery Chemistry
Merck

Hubert Haag, Director Lead Discovery – Global Sourcing & External Business Opportunities
Sanofi

Mike Hann, GSK Senior Fellow & Director, Drug Design & Selection
GlaxoSmithKline

Rob Howes, Director Reagents and Assay Development, Discovery Sciences
AstraZeneca

Malin Lemurell, Director of Medicinal Chemistry
AstraZeneca

Matt Lucas, Director of Chemistry
Yumanity Therapeutics

Wei-Sheng Huang, Director of Discovery Chemistry
Takeda

Daniel Zwilling, Director of CNS Discovery
Circuit Therapeutics

Jose Duca, Head, Computer-Aided Drug Discovery
Novartis

Ulrich Schopfer, Head Integrated Target and Lead Discovery
Novartis

Christoph Dumelin, Laboratory Head
Novartis

Florian Fuchs, CBT Screening Sciences, Head Cellular Assays
Novartis

Gerhard Hessler, Head of Computational and Structural Drug Design
Sanofi

Tobias Gabriel, Head External Drug Discovery
Novartis

Lutz Mueller, Expert Toxicology Project Leader
F. Hoffmann-La Roche

Hasane Ratni, Senior Principal Scientist
F. Hoffmann-La Roche

Mike Morrison, Principal Scientist
Epizyme

Anthony Donofrio, Senior Scientist HTE and Lead Discovery Capabilities
Merck

Steve Andrews, Head of Chemistry
Cambridge Drug Discovery Institute

Paul Andrews, Director of Operations, National Phenotypic Screening Centre
University of Dundee

Rod Hubbard, Senior Fellow and Professor
Vernalis and University of York

Ernesto Freire, Henry Walters Professor
Johns Hopkins University

https://www.drugdiscovery-summit1.com/book-online/